Biocorp’s business development team is keeping the pedal to the metal. Days after disclosing news of its deal with Merck KGaA, the delivery systems player revealed a pact with BD to use connected technology to track adherence for self-administered injectable drugs.
The partnership is built on Biocorp’s Injay technology. France-based Biocorp developed the technology to enable companies to add connectivity to prefilled syringes. The device has a near-field communication (NFC) tag on the piston rod that contains information such as the type of drug, concentration, batch number and expiry date.
When the device detects a complete injection, it can send the time-stamped product information to a NFC reader to confirm the delivery of the treatment. Biocorp designed Injay to be adaptable to any size of prefilled syringe.
BD sees the technology as a good fit for its UltraSafe Plus passive needle guard, a device intended to enable single-handed self-administration of injectable medicines. The companies will work to integrate Injay into UltraSafe Plus. Matthew Schabacker, vice president and general manager of advanced drug delivery solutions at BD, explained the thinking behind the integration in a statement.
“Connected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence. Our agreement with Biocorp enables us to explore innovative solutions in this market and further supports BD’s commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes,” he said.
The agreement adds BD to a roster of Biocorp partners that also includes Merck KGaA, Novo Nordisk and Sanofi. Biocorp has secured the deals using technology such as Mallya, a clip-on Bluetooth device for use with pen injectors.
By Nick Paul Taylor
Source: fiercepharma.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
